<DOC>
	<DOCNO>NCT00002498</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Giving drug different combination may kill tumor cell . PURPOSE : Randomized phase II trial compare effectiveness cyclophosphamide , methotrexate , fluorouracil mitoxantrone treat old patient recurrent metastatic breast cancer .</brief_summary>
	<brief_title>Combination Chemotherapy Compared With Mitoxantrone Treating Older Patients With Advanced Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine response rate duration response elderly patient advance breast cancer treat first-line chemotherapy mitigate `` classical '' CMF ( cyclophosphamide/methotrexate/fluorouracil ) vs. mitoxantrone ( DHAD ) . II . Define morbidity CMF DHAD elderly patient . III . Determine quality life patient . OUTLINE : This randomize study . Patients stratify participate institution . The first group receive oral cyclophosphamide day 1 14 intravenous methotrexate fluorouracil day 1 8 . Courses repeat every 4 week maximum 6 course . The second group receive intravenous mitoxantrone every 3 week maximum 8 course . Concomitant therapy hepatotoxic nephrotoxic drug ( e.g. , NSAIDs ) corticosteroid ( even antiemetic ) permit either group . Radiotherapy allow provide 50 % bone marrow irradiate least 1 indicator lesion unirradiated . Patients complete therapy follow every 3 month disease progression . PROJECTED ACCRUAL : 60 patient accrue approximately 1 year . If extreme difference arm exist entry 30 patient , accrual may stop early .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Mitoxantrone</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven , progressive , recurrent metastatic breast cancer patient 70 year age Measurable evaluable disease require , include : Lesions mediastinum , retroperitoneum , liver least 3 cm diameter CT scan ultrasound The following consider measurable evaluable : Lymphedema Hilar enlargement Pleural effusion Ascites Bone marrow infiltration Osteoblastic skeletal lesion No CNS metastases Hormone receptor status : Not specify PATIENT CHARACTERISTICS : Age : Over 70 Sex : Not specify Menopausal status : Postmenopausal Performance status : WHO 02 Hematopoietic : WBC least 3,000 Platelets least 100,000 Hepatic : Bilirubin le 1.4 mg/dL ( 25 micromoles/L ) Renal : Creatinine clearance ( calculate ) great 50 mL/min patient weigh least 45 kg measure creatinine clearance least 50 mL/min patient weigh less 45 kg Cardiovascular : No congestive heart failure No myocardial infarction within 6 month No severe arrhythmia No complete bundle branch block Other : No active uncontrolled infection No mental disorder may preclude patient followup No second malignancy except : Adequately treat basal cell carcinoma skin Adequately treat situ carcinoma cervix PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior chemotherapy advance disease At least 1 year since prior adjuvant chemotherapy Endocrine therapy : At least 4 week since prior estrogen , androgen , progestin Tamoxifen aminoglutethimide allow wait period disease progress Recovery prior hormonal therapy metastatic disease require Radiotherapy : Prior radiotherapy allow provide : Evaluable disease exist outside treatment field No great 50 % bone marrow irradiate Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>70 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2000</verification_date>
	<keyword>stage IV breast cancer</keyword>
	<keyword>recurrent breast cancer</keyword>
</DOC>